Dr Cathy O’Hare
Chief Development Officer
Cathy is based in our San Francisco Operations hub and co-leads Perspectum’s Imaging CRO Business Unit.
Cathy has over a decade of experience in translational research, including expertise in clinical biomarker and diagnostic development for NASH and associated metabolic indications. Cathy completed her PhD at UCSF, followed by postdoctoral research fellowships at the University of Cambridge and UC Berkeley. Most recently, Cathy led biomarker development for multiple clinical development programs at Medivation, prior to its acquisition by Pfizer. This included leading biomarker and diagnostic strategy and operations for a clinical-stage NASH program.